Field Sales Rare Disease @ Ultragenyx Pharmaceutical

Why Join Us?

Be a hero for our rare disease patients

At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them.

Our commitment and care for patients extends to our people, so culture is an essential cornerstone for Ultragenyx. We remain continuously focused on creating a supportive and inclusive environment of profound learning and growth – so employees can thrive in all areas of their lives, in and outside of work. Ultimately, we want to be an organization where we would be proud for our family, friends and children to work.

If you want to have a meaningful impact, do the best work of your career, and grow a lot, both professionally and personally, come join our team.

Position Summary:

ultradedicated – Your biggest challenges yield rare possibilities

We are looking for experienced UltraCare Liaisons (UCLs) that will represent Ultragenyx in the Rare Disease Community, responsible for the promotion of Dojolvi for the treatment of long chain fatty oxidation disorders (LC-FAOD), Fayuvi, a gene therapy treatment of Sanfilippo syndrome Type A (MPSIIIA), and Genglycos, a gene therapy treatment for Glycogen Storage Disease Type 1a (GSD1a). We are seeking driven individuals with the desire to run their own business within a specified geography. These individuals will have strong business acumen, be able to drive change through innovative approaches, demonstrate excellent communication skills, and consistently deliver sales results.

Work Model:

Field: Officially documented as working as a member of the Ultragenyx field team, generally interacting with third parties on behalf of Ultragenyx.

Territory includes: Illinois, Kansas and Missouri -Must live in territory geography. Territory subject to change based on business need

Responsibilities:

Serve as territory business owner with a focus upon impact and territory analysis. Other key areas of focus include optimizing: i) patient diagnosis and care through HCP education, ii) educating HCPs about Ultragenyx approved products, iii) assisting with treatment fulfillment

Ability to develop and nurture effective business relationship management with key stakeholders, including HCPs, Registered Dieticians, Genetic Counselors, Pharmacists, and related support staff

Proactively builds effective working relationships with internal/external stakeholders; can drive agreement/decisions from multiple stakeholders; ability to understand people’s emotions and flex communication style. Can adjust their approach based on different stakeholder needs, concerns, or audience members to drive alignment and meet their work goals.

Develop and maintain a strategic territory business plan focused on key academic centers, community targets within priority specialties, territory opportunities and challenges.

Determines and implements suitable travel schedule and call plan on a daily/weekly basis to ensure both adequate and highly effective coverage for all key accounts.

Executes programs, high impact in-services, and other educational opportunities for their territory.

Timely completion of compliance trainings, internal product & disease state trainings, Veeva administration, monthly expense reports, and all other administration expectations.

Requirements:

Bachelor’s Degree required

8 years with 5+ years being in the healthcare/biotech industry, inclusive of 3 years of field-based experience in account management, sales, and/or field reimbursement. Rare disease experience is preferred.

Experience launching biopharma/pharma products successfully is preferred

Documented track record of field sales success

Strategic business acumen and cross-functional and collaborative leadership with internal stakeholders including marketing, medical, clinical operations, and patient services.

Demonstrated experience effectively presenting clinical/scientific information required

Approximately 50 - 60% (dependent on geography) travel is required; overnight travel is required as needed

Must live in territory geography. Territory includes: Illinois, Kansas and Missouri Territory subject to change based on business need

#LI-CS1 #LI-Remote

The typical annual salary range for this full-time position is listed below. This range reflects the characteristics of the job, such as required skills and qualifications and is based on the office location noted in this job posting. The range may also be adjusted based on applicant's geographic location.

This position is eligible for annual bonus and equity incentives. Actual individual pay is determined by demonstrated experience and internal equity alignment.

Pay Range

$153,100—$189,100 USD

Full Time employees across the globe enjoy a range of benefits, including, but not limited to:

· Generous vacation time and public holidays observed by the company

· Volunteer days

· Long term incentive and Employee stock purchase plans or equivalent offerings

· Employee wellbeing benefits

· Fitness reimbursement

· Tuition sponsoring

· Professional development plans

* Benefits vary by region and country

Ultragenyx Pharmaceutical is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital and veteran status, and any other status or classification protected by applicable federal, state, and/or local laws. Reasonable accommodation will be provided for all protected statuses or classifications protected by applicable law, including individuals with disabilities, disabled veterans, for pregnancy, childbirth, and related medical conditions, and based on sincerely held religious beliefs. Applicants can request an accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application, or in any part of the recruitment process, you may contact Talent Acquisition by emailing us at [email protected].

See our CCPA Employee and Applicant Privacy Notice.

See our Privacy Policy.

Note to External Recruiters: All candidate activity and open positions are managed strictly through our Human Resources Department. Our Human Resources Department kindly requests that recruiters not contact employees/hiring managers directly in an attempt to solicit business and present candidates. Please note that failure to comply with this request will be a factor in determining a professional relationship with our organization. Submission of unsolicited resumes prior to an agreement set in place between the Human Resources Department and the recruiting agency will not create any implied obligation. Inquiries on developing a recruiting relationship with us, may be directed to: [email protected].

Pay Range 153100 - 189100 USD

About the company

Ultragenyx Pharmaceutical develops and commercializes therapies for rare and ultra-rare genetic diseases. It advances a diversified pipeline and brings FDA-approved drugs, like burosumab for Tumor Induced Osteomalacia and UX007 for Long-chain Fatty Acid Oxidation Disorders, to market while ensuring continuous supply for patients. The company differentiates itself through a broad portfolio focused on high-need, niche conditions and a strong emphasis on uninterrupted patient access. Its goal is to turn scientific research into accessible treatments and lead the rare-disease market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Novato, California

Founded

2010

Get referred to Ultragenyx Pharmaceutical

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA approved FAYUVI on September 17, 2026, Ultragenyx's second gene-therapy approval.
FDA approved GENGLYCOS on August 19, 2026, adding a first-in-class GSDIa launch.
Q2 2026 revenue reached $214 million, and management reaffirmed 2027 profitability targeting lower spending.

What critics are saying

Pomerantz opened a securities investigation on September 24, 2026 after GTX-102's collapse.
GTX-102 missed both Phase 3 Aspire endpoints on September 2, 2026, crushing confidence.
GENGLYCOS faces accelerated-approval confirmatory obligations; failure removes approval, revenue, and credibility by 2028.

What makes Ultragenyx Pharmaceutical unique

Ultragenyx owns an unusually deep rare-disease launch engine: Crysvita, Dojolvi, Evkeeza, Mepsevii.
Bedford, Massachusetts manufacturing supports GENGLYCOS and FAYUVI commercialization, reducing external supply dependence.
Ultragenyx spans metabolic and neurogenetic diseases, giving it multiple shots within one niche.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation
Volunteer Days
Stock Options
Company Equity
Wellness Program
Professional Development Budget
Tuition Reimbursement

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-1%

2 year growth

-1%

NPR

Oct 23rd, 2026

Family-funded Sanfilippo gene therapy wins FDA approval with a nearly $4M price tag

The US Food and Drug Administration has approved Fayuvi, the first treatment for Sanfilippo syndrome, a rare inherited disease that usually kills children before adulthood. Ultragenyx set the one-time gene therapy's price at nearly $4 million. The research began with Haiyan Fu at Nationwide Children's Hospital in Columbus, Ohio, who worked on the therapy in mice from the late 1990s. Eight family foundations kept her work alive until it was ready for human trials. Eliza O'Neill was diagnosed in 2013. Her parents raised more than $2 million, including a record-setting GoFundMe campaign in 2014, and she was the first patient treated, in 2016. Ultragenyx acquired the rights in 2022. Eliza, almost 17, still cannot speak but attends school and communicates with picture cards and devices.

Yahoo Finance

Oct 14th, 2026

Ultragenyx H1 revenue up 14% to $350M as two new gene therapies widen its portfolio

Ultragenyx Pharmaceutical is widening its rare-disease portfolio, with two gene therapies newly approved in the US. It reported $350 million in revenue for the first half of 2026, up 14% year over year. Crysvita remains the main driver, at $249 million, or about 71% of the total. Evkeeza, sold outside the US, brought in $39 million, up 56%. The US Food and Drug Administration approved Genglycos in August and Fayuvi in September. Ultragenyx agreed to sell the priority review voucher from Genglycos for $210 million, though 20% of gross proceeds is payable to the National Institutes of Health. Full-year revenue guidance of $730 million to $760 million excludes new launches. Shares have fallen 35.1% this year.

Asianet News

Oct 7th, 2026

Ultragenyx lands $210M deal to sell FDA Priority Review Voucher - Retail sees 'huge' buying opportunity.

Ultragenyx lands $210M deal to sell FDA Priority Review Voucher - Retail sees 'huge' buying opportunity. Published: Oct 07 2026, 10:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August. * A Priority Review Voucher lets its recipient request a faster review of a future drug application or sell the voucher to another company. * The company said proceeds will support rare-disease programs and its path toward profitability. * The latest deal marks Ultragenyx's third PRV sale, with the previous two in 2018. Shares of Ultragenyx Pharmaceutical (RARE) were in focus after the biotech company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, giving it sizeable non-dilutive capital to support its pipeline. RARE shares were up 4% at the time of writing, bucking the broader market drawdown and on track for their biggest single-day gain so far this month. Genglycos is Ultragenyx's third PRV sale. A Priority Review Voucher (PRV) lets its recipient request a faster review of a future drug application with the U.S. Food and Drug Administration (FDA) or sell the voucher to another company. The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August. Ultragenyx said proceeds from the sale will help fund development of additional rare and ultra-rare disease treatments. "Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability," said Howard Horn, Ultragenyx's CFO. The latest deal marks Ultragenyx's third PRV sale, after the company sold its first two vouchers in 2018 for a combined $210.6 million. RARE still has four therapies in pipeline. Ultragenyx's pipeline includes four experimental therapies for brain, liver and muscle-related diseases. It also markets four drugs - Crysvita, Dojolvi, Evkeeza and Mepsevii - for a range of rare bone, metabolic, cholesterol and genetic disorders. The latest cash infusion adds to Ultragenyx's $436 million in cash, cash equivalents and marketable securities as of June 30. Retail sees 'huge' buying opportunity. Retail sentiment surrounding RARE on Stocktwits remained in the 'bearish' zone over the past 24 hours. One user saw a "huge buying opportunity" with RARE close to a breakout. View this Stocktwits post The stock has been under significant selling pressure this year, falling more than 36%. Also read: FCEL Stock Slumps Amid CFO Transition - But Retail Calls Ex-Xylem Hire An 'Encouraging Sign' For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

PR Newswire

Sep 24th, 2026

INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Ultragenyx Pharmaceutical Inc. - RARE.

INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Ultragenyx Pharmaceutical Inc. - RARE. Sep 24, 2026, 17:34 ET NEW YORK, Sept. 24, 2026 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On September 2, 2026, Ultragenyx issued a press release "announc[ing] results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome." Per the press release, "[t]he study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)." On this news, Ultragenyx's stock price fell $11.68 per share, or 44.03%, to close at $14.85 per share on September 3, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. SOURCE Pomerantz LLP

Yahoo Finance

Sep 22nd, 2026

Ultragenyx gains first Sanfilippo syndrome Type A treatment approval, eyes 2027 profitability with $3.95M therapy

Ultragenyx Pharmaceutical received FDA approval on 17 September for Fayuvi, the first treatment for neurologic manifestations of Sanfilippo syndrome Type A in paediatric patients. The stock jumped over 12% on the news but remains down nearly 40% for the year. The approval strengthens Ultragenyx's 2027 profitability target. The company posted a $575 million loss on $673 million revenue in 2025 and projects $730 million to $760 million in 2026 revenue from current products, excluding new launches. Fayuvi carries a $3.95 million list price for one-time treatment. JP Morgan estimates peak global sales of $200 million to $250 million, representing roughly 26% of Ultragenyx's 2026 revenue guidance at the lower end. The drug will become available to patients within 30 to 60 days. Hedge fund holdings fell to 50 in Q2 from 55 in Q1, though AQR Capital Management increased its stake 44% to 6.6 million shares.

Ultragenyx Pharmaceutical

Field Sales Rare Disease - Inborn Errors of Metabolism

About the job

Position Summary:

Work Model:

Responsibilities:

Requirements:

About the company

Get referred to Ultragenyx Pharmaceutical

Simplify's Take

What believers are saying

What critics are saying

What makes Ultragenyx Pharmaceutical unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth